At Pfizer, we are investing in next-generation science and technology to invent tomorrow’s innovative therapies. The breadth and depth of our colleagues’ technical expertise is second to none, and underpins our approach to the discovery and development of medicines and vaccines. The Medicinal Sciences group has a central role in this endeavor, from the conception of an idea all the way through to the delivery of a new therapy to patients.
Pfizer's rich and diverse pipeline includes small-molecule drugs, large-molecule biotherapeutics such as antibodies, as well cell- and gene-based therapies and vaccines. For each of these programs, Pfizer scientists draw on a wealth of state-of-the-art science and technology, spanning many disciplines, with a single aim: to bring a new best-in-class treatment to patients.
in this process.
At the forefront of this innovation are colleagues from the Medicinal Sciences group, a division of Pfizer’s Worldwide Research and Development organization. Medicinal Sciences is structured so as to reflect our colleagues’ invaluable expertise across a range disciplines, and each key function – Medicine Design, BioMedicine Design, Small Molecule and Biotherapeutics Product and Process Development, and Clinical Trial Supply – has a critical role to play.
What We’re Working On
When Pfizer's scientists identify a potential target that may play a role in disease pathology, Medicinal Sciences colleagues begin the multi-faceted process of designing and creating a molecule that can change the function of that target and be used as a safe and effective therapy for patients. Once the molecule itself has been designed, Medicinal Sciences colleagues establish the manufacturing process and produce the supplies that are used in clinical studies. Accomplishing these tasks involves answering many questions – including: